Imexpharm Corporation (HOSE: IMP)

Imexpharm Balance Sheet

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	127,521	106,201	178,845	271,273	85,269	75,036
Short-Term Investments	132,000	93,000	211,300	111,300	60,340	1,500
Trading Asset Securities	-	-	-	1,153	3,268	3,688
Cash & Short-Term Investments	259,521	199,201	390,145	383,726	148,877	80,223
Cash Growth	-29.82%	-48.94%	1.67%	157.75%	85.58%	-58.80%
Accounts Receivable	335,094	254,058	228,770	241,946	328,134	247,577
Other Receivables	5,620	4,066	-1,000	11,995	17,650	10,258
Receivables	340,714	258,124	227,770	255,941	345,784	257,835
Inventory	713,158	699,446	435,841	492,075	424,237	350,457
Prepaid Expenses	4,724	6,539	1,601	3,155	2,031	487.31
Other Current Assets	41,158	43,825	48,195	41,443	61,046	90,752
Total Current Assets	1,359,275	1,207,135	1,103,553	1,176,340	981,975	779,755
Property, Plant & Equipment	878,066	908,754	996,450	955,680	949,147	896,180
Long-Term Investments	71,283	71,284	71,290	50,962	51,669	51,678
Other Intangible Assets	75,063	74,150	72,978	73,581	76,563	71,082
Other Long-Term Assets	121,305	131,293	32,672	38,136	37,101	46,110
Total Assets	2,504,992	2,392,615	2,276,944	2,294,700	2,096,455	1,847,174
Accounts Payable	71,752	72,127	87,542	92,713	59,704	90,859
Accrued Expenses	113,322	144,776	139,803	100,346	112,446	103,111
Short-Term Debt	96,413	49,422	-	80,491	130,928	37,579
Current Portion of Long-Term Debt	-	-	94,980	91,652	-	-
Current Income Taxes Payable	16,995	19,107	25,382	17,141	12,688	7,799
Current Unearned Revenue	40,550	-	-	-	-	-
Other Current Liabilities	88,296	22,605	34,789	26,295	31,167	23,106
Total Current Liabilities	427,328	308,036	382,497	408,638	346,932	262,454
Long-Term Debt	-	-	-	91,652	-	-
Other Long-Term Liabilities	-	-	-	-	19,037	25,831
Total Liabilities	427,328	308,036	382,497	500,290	365,969	288,285
Common Stock	700,384	700,384	667,054	667,054	667,054	494,212
Additional Paid-In Capital	507,368	507,368	507,368	507,368	507,368	601,241
Retained Earnings	867,849	874,764	717,963	617,926	554,002	461,374
Treasury Stock	-358.6	-358.6	-358.6	-358.6	-358.6	-358.6
Comprensive Income & Other	2,421	2,421	2,421	2,421	2,421	2,421
Shareholders' Equity	2,077,664	2,084,579	1,894,447	1,794,410	1,730,486	1,558,889
Total Liabilities & Equity	2,504,992	2,392,615	2,276,944	2,294,700	2,096,455	1,847,174
Total Debt	96,413	49,422	94,980	263,795	130,928	37,579
Net Cash (Debt)	163,108	149,779	295,165	119,931	17,949	42,644
Net Cash Growth	-13.91%	-49.26%	146.11%	568.18%	-57.91%	-78.10%
Net Cash Per Share	1059.08	972.52	1916.53	778.71	119.94	287.41
Filing Date Shares Outstanding	154.01	154.01	154.01	154.01	154.01	148.31
Total Common Shares Outstanding	154.01	154.01	154.01	154.01	154.01	148.31
Working Capital	931,947	899,099	721,056	767,702	635,043	517,301
Book Value Per Share	13490.43	13535.33	12300.70	11651.16	11236.10	10511.00
Tangible Book Value	2,002,601	2,010,429	1,821,469	1,720,829	1,653,923	1,487,807
Tangible Book Value Per Share	13003.04	13053.86	11826.85	11173.39	10738.97	10031.72
Buildings	384,650	384,597	299,061	298,602	262,381	249,146
Machinery	1,082,720	1,066,310	638,041	601,972	578,380	523,755
Construction In Progress	48,179	47,351	580,743	519,463	522,447	490,298

Source: S&P Capital IQ. Standard template. Financial Sources.